Nanobiotix names Arnd Christ as new chief financial officer

Nanobiotix announced on October 1, 2026 that Arnd Christ has been appointed chief financial officer and a member of the company's executive board, effective October 1, 2026.¹ The Paris- and Cambridge, Mass.-based company describes itself as a late-stage clinical biotechnology company focused on physics-based approaches for cancer and other major diseases.¹

Christ takes over from Bart Van Rhijn, who is stepping down from his roles as chief financial and business officer and executive board member following five years with the company.¹

According to the release, Christ has more than two decades of financial leadership experience at publicly listed biotechnology companies in Europe and the United States.¹ He most recently served as chief financial officer of Immatics N.V., a Nasdaq-listed biotechnology company, from October 2020 to September 2025.¹ Earlier in his career, he held CFO roles at several private and public European biotech firms, including InflaRx N.V., MediGene AG, NovImmune SA and Probiodrug AG, and also served on the supervisory board of Immunocore.¹ The company noted that his career has included work on a range of corporate transactions, including initial public offerings, licensing agreements and fundraising efforts for both private and publicly traded biotech companies.¹

In a statement, Christ said the company is "at a defining point in its history, moving from a story carried primarily by one asset to one that is informed by multiple platforms."¹

Nanobiotix chairman Laurent Levy thanked Van Rhijn, saying his leadership "helped drive the strengthening of both our financial and business foundation while positioning Nanobiotix for the opportunities ahead."¹

The company noted that it was incorporated in 2003, is headquartered in Paris, has traded on Euronext Paris since 2012 and on Nasdaq since December 2020, and maintains subsidiaries including one in Cambridge, Massachusetts.¹